EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hypoperfusion in early-phase amyloid PET as a predictor of cognitive decline in Alzheimer's disease

A Škorvagová iD, F Ribaldi iD, J Cerman iD, C Wang iD, M Scheffler iD, A J Mendes iD, C Wyss-Dominguez iD, V Garibotto iD, G Frisoni iD, R Andel iD, C Boccalini iD, J Hort iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026-05 · 53 (6) · 4037-4049

DOI: 10.1007/s00259-025-07694-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 02.03.2026. Verfasst von A Škorvagová und 11 weiteren Autor:innen. Beteiligte Einrichtung: Memory Clinic, Department of Neurology, Charles University in Prague, 2Nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Alzheimer Disease, Cognitive Dysfunction, Amyloid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charles University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Dual-phase amyloid PET enables concurrent assessment of amyloid burden and cerebral perfusion, providing both molecular and functional information within a single visit. While amyloid PET is well validated diagnostically, the prognostic value of early-phase perfusion remains less explored. We aimed to determine whether perfusion in Alzheimer’s disease (AD)–relevant regions is associated with longitudinal cognitive trajectories.

Methods

We analyzed 218 participants from a memory-clinic cohort ranging from cognitively unimpaired (CU, n = 65) to mild cognitive impairment (MCI, n = 115) and dementia (n = 38). Based on visual read of late-phase amyloid PET, 123 participants were classified as amyloid-positive (Aβ+) and 93 as amyloid-negative (Aβ–). The groups differed significantly in age, education, and baseline MMSE (all p < 0.01), but not in sex distribution. Early-phase perfusion was quantified as standardized uptake value ratios (SUVr) within an AD meta–region of interest (posterior cingulate, angular, and temporal cortex) and analyzed using linear mixed-effects models adjusting for age, sex, education, APOE ε4 genotype, and white matter lesion burden.

Results

Among Aβ+ participants, 11 were CU, 79 MCI, and 33 dementia; among Aβ– participants, 53 were CU, 35 MCI, and 5 dementia. Perfusion declined progressively across clinical stages (CU > MCI > dementia) and was positively correlated with baseline MMSE (r = 0.39, p < 0.001). In Aβ+ individuals, higher baseline perfusion predicted slower MMSE decline over time (interaction β = 5.85, p < 0.001), whereas no such association was observed in the Aβ– group. No significant association was observed in amyloid-negative participants. These effects remained significant after adjustment for vascular and genetic covariates and were independent of amyloid plaque burden.

Conclusion

Perfusion derived from early-phase amyloid PET in AD-related regions is a reliable marker of cognitive status and progression in individuals with confirmed amyloid pathology. These findings highlight the added value of dual-phase PET as a practical, single-visit approach for combined diagnostic and prognostic evaluation, particularly where additional functional imaging is not feasible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyAlzheimer DiseaseCognitive DysfunctionAmyloidCerebrovascular CirculationHumansFemaleMaleAged

Stichwörter der Autor:innen

Alzheimer diseaseAmyloid PETCerebral perfusionCognitive declineEarly-phase imagingPrognostic biomarker

Substanzen

Amyloid

Autor:innen und Institutionen

  • Memory Clinic, Department of Neurology, Charles University in Prague, 2Nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
  • Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.
  • Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
  • Memory Clinic, Department of Neurology, Charles University in Prague, 2Nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. jiri.cerman@fnmotol.cz.
  • Division of Radiology, Geneva University Hospitals, Geneva, Switzerland.
  • Genomic Molecular Diagnostics Laboratory, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland.

ORCID-Profile: A Škorvagová, F Ribaldi, J Cerman, C Wang, M Scheffler, A J Mendes, C Wyss-Dominguez, V Garibotto, G Frisoni, R Andel, C Boccalini, J Hort

Förderung

  • Charles University

Zitieren

APA

Škorvagová, A., Ribaldi, F., Cerman, J., Wang, C., Scheffler, M., Mendes, A. J., Wyss-Dominguez, C., Garibotto, V., Frisoni, G., Andel, R., Boccalini, C., & Hort, J. (2026). Hypoperfusion in early-phase amyloid PET as a predictor of cognitive decline in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 53(6), 4037-4049. https://doi.org/10.1007/s00259-025-07694-1

Vancouver

Škorvagová A, Ribaldi F, Cerman J, Wang C, Scheffler M, Mendes AJ, et al. Hypoperfusion in early-phase amyloid PET as a predictor of cognitive decline in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(6):4037-4049. doi:10.1007/s00259-025-07694-1

BibTeX
@article{korvagov2026,
  author = {Škorvagová, A and Ribaldi, F and Cerman, J and Wang, C and Scheffler, M and Mendes, A J and Wyss-Dominguez, C and Garibotto, V and Frisoni, G and Andel, R and Boccalini, C and Hort, J},
  title = {Hypoperfusion in early-phase amyloid PET as a predictor of cognitive decline in Alzheimer's disease},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {6},
  pages = {4037--4049},
  doi = {10.1007/s00259-025-07694-1}
}
Kostenlos starten →